| [1] |
Modrich P. Mechanisms and biological effects of mismatch repair [J]. Annu Rev Genet, 1991，25：229-253.
|
| [2] |
Lipkin SM, Wang V, Jacoby R, et al. MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability[J]. Nat Genet, 2000，24(1)：27-35.
|
| [3] |
Steinke V, Engel C, Büttner R, et al. Hereditary nonpolyposis colorectal cancer (HNPCC)/Lynch syndrome[J]. Dtsch Arztebl Int, 2013，110(3)：32-38.
|
| [4] |
Svrcek M, Lascols O, Cohen R, et al. MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors[J]. Bull Cancer, 2019，106(2)：119-128.
|
| [5] |
Latham A, Srinivasan P, Kemel Y, et al. Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer [J]. J Clin Oncol, 2019，37(4)：286-295.
|
| [6] |
Sha D, Jin Z, Budczies J, et al. Tumor mutational burden as a predictive biomarker in solid tumors[J]. Cancer Discov, 2020, 10(12)：1808-1825.
|
| [7] |
Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100 000 human cancer genomes reveals the landscape of tumor mutational burden[J]. Genome Med, 2017，9(1)：34.
|
| [8] |
Zhuang W, Ma J, Chen X, et al. The tumor mutational burden of Chinese advanced cancer patients estimated by a 381-cancer-gene panel[J]. J Cancer, 2018，9(13)：2302-2307.
|
| [9] |
Xu J, Guo X, Jing M, et al. Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67[J]. Onco Targets Ther, 2018，11：2269-2275.
|
| [10] |
Xu J, Bao H, Wu X, et al. Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer[J]. Oncol Lett, 2019，18(1)：449-455.
|
| [11] |
Voutsadakis IA. High tumor mutation burden and other immunotherapy response predictors in breast cancers: associations and therapeutic opportunities[J]. Target Oncol, 2020，15(1)：127-138.
|
| [12] |
Giannakis M, Mu XJ, Shukla SA, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma[J]. Cell Rep, 2016，15(4)：857-865.
|
| [13] |
Luchini C, Bibeau F, Ligtenberg MJL, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach[J]. Ann Oncol, 2019，30(8)：1232-1243.
|
| [14] |
Barroso-Sousa R, Jain E, Cohen O, et al. Prevalence and mutational determinants of high tumor mutation burden in breast cancer[J]. Ann Oncol, 2020，31(3)：387-394.
|
| [15] |
Fusco N, Lopez G, Corti C, et al. Mismatch repair protein loss as a prognostic and predictive biomarker in breast cancers regardless of microsatellite instability[J]. JNCI Cancer Spectr, 2018，2(4)：pky056.
|
| [16] |
Cheng AS, Leung SCY, Gao D, et al. Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort [J]. Breast Cancer Res Treat, 2020，179(1)：3-10.
|
| [17] |
Davies H, Morganella S, Purdie CA, et al. Whole-genome sequencing reveals breast cancers with mismatch repair deficiency.[J] Cancer Res, 2017，77(18)：4755-4762.
|
| [18] |
Nguyen-Dumont T, Steen JA, Winship I, et al. Mismatch repair gene pathogenic germline variants in a population-based cohort of breast cancer[J]. Fam Cancer, 2020，19(3)：197-202.
|
| [19] |
Lopez G, Fusco N. RE: Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort[J]. Breast Cancer Res Treat, 2020，180(1)：265-266.
|
| [20] |
Kappil M, Terry MB, Delgado-Cruzata L，et al. Mismatch repair polymorphisms as markers of breast cancer prevalence in the breast cancer family registry[J]. Anticancer Res, 2016，36(9)：4437-4441.
|
| [21] |
Espenschied CR, LaDuca H, Li S, et al. Multigene panel testing provides a new perspective on Lynch syndrome[J]. J Clin Oncol, 2017，35(22)：2568-2575.
|
| [22] |
Roberts ME, Jackson SA, Susswein LR, et al. MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer[J]. Genet Med, 2018，20(10)：1167-1174.
|
| [23] |
Sheehan M, Heald B, Yanda C, et al. Investigating the link between Lynch syndrome and breast cancer[J]. Eur J Breast Health, 2020，16(2)：106-109.
|
| [24] |
National Comprehensive Cancer Network. NCCN practice guidelines: genetic/familial high-risk assessment: breast, ovarian, and pancreatic. version 2.2021[EB/OL]. [2021-04-05].
URL
|
| [25] |
Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast --screening with MRI as an adjunct to mammography[J]. CA Cancer J Clin, 2007，57(2)：75-89.
|
| [26] |
Monticciolo DL, Newell MS, Moy L, et al. Breast cancer screening in women at higher-than-average risk: recommendations from the ACR[J]. J Am Coll Radiol, 2018，15(3 Pt A)：408-414.
|
| [27] |
Sorscher S. The importance of distinguishing sporadic cancers from those related to cancer predisposing germline mutations[J]. Oncologist, 2018，23(11)：1266-1268.
|
| [28] |
Sorscher S. Rationale for evaluating breast cancers of Lynch syndrome patients for mismatch repair gene expression[J]. Breast Cancer Res Treat, 2019，178(2)：469-471.
|
| [29] |
Kanaya N, Tanakaya K, Yamasaki R, et al. Clinicopathological features of breast cancer in Japanese female patients with Lynch syndrome[J]. Breast Cancer, 2019，26(3)：359-364.
|
| [30] |
Smolarz B, Makowska M, Samulak D, et al. Gly322Asp and Asn127Ser single nucleotide polymorphisms (SNPs) of hMSH2 mismatch repair gene and the risk of triple-negative breast cancer in Polish women[J]. Fam Cancer, 2015，14(1)：81-88.
|
| [31] |
Malik SS, Zia A, Mubarik S, et al. Correlation of MLH1 polymorphisms, survival statistics, in silico assessment and gene downregulation with clinical outcomes among breast cancer cases[J]. Mol Biol Rep, 2020，47(1)：683-692.
|
| [32] |
Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints[J]. Cancer Discov, 2015，5(1)：43-51.
|
| [33] |
Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015，372(26)：2509-2520.
|
| [34] |
Prasad V, Kaestner V, Mailankody S. Cancer drugs approved based on biomarkers and not tumor type-FDA approval of pembrolizumab for mismatch repair-deficient solid cancers[J]. JAMA Oncol, 2018，4(2)：157-158.
|
| [35] |
Mills AM, Dill EA, Moskaluk CA, et al. The relationship between mismatch repair deficiency and PD-L1 expression in breast carcinoma[J]. Am J Surg Pathol, 2018，42(2)：183-191.
|
| [36] |
Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer[J]. N Engl J Med, 2018，379(22)：2108-2121.
|
| [37] |
US Food and Drug Administration. FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple negative breast cancer[EB/OL]. [2021-04-05].
URL
|
| [38] |
Haricharan S, Punturi N, Singh P, et al. Loss of MutL disrupts CHK2-dependent cell-cycle control through CDK4/6 to promote intrinsic endocrine therapy resistance in primary breast cancer[J]. Cancer Discov, 2017，7(10)：1168-1183.
|